Une étude de phase 3, randomisée, en double aveugle, contrôlée par placebo, à 3 bras pour étudier la sécurité et l'efficacité de l'Efimosfermin Alfa chez les participants atteints de stéatohépatite métabolique associée à une dysfonction métabolique confirmée par biopsie de stade F2 ou F3 (MASH) (ZENITH-1)
This research study, called ZENITH-1, is looking into a new treatment called Efimosfermin alfa for people diagnosed with Metabolic Dysfunction-Associated Steatohepatitis (MASH). MASH is a liver condition that causes inflammation and scarring. The main aim is to find out if this new medicine can help improve liver scarring (fibrosis) and reduce the liver damage caused by MASH. Some participants will receive the new medicine, while others will get a placebo (a dummy treatment with no active ingredients). This will help doctors understand how effective and safe Efimosfermin alfa is in improving liver health and preventing serious liver problems over time. The study will last for a number of years, with regular check-ups to monitor progress.
En un coup d'œil
De quoi parle cette étude ?
This study, called ZENITH-1, is designed to test a new medicine, Efimosfermin alfa, for people with a liver condition called MASH (Metabolic Dysfunction-Associated Steatohepatitis). MASH is a serious type of fatty liver disease where there's inflammation and damage, which can lead to scarring (fibrosis) in the liver. This scarring can eventually become severe and cause serious health problems.
The main goal of this study is to see if Efimosfermin alfa can help reduce this liver scarring and improve the overall health of the liver. We also want to find out if it can help resolve the inflammation and fat build-up in the liver. To do this, some people in the study will receive the active medicine, while others will receive a placebo, which looks like the medicine but doesn't contain any active ingredients. This is a common way to test new medicines and helps us compare the effects fairly.
The researchers will closely monitor participants for a long time, checking how their liver changes and if the medicine helps prevent serious liver-related problems. They will also keep a close eye on any side effects to make sure the treatment is safe. By comparing the groups, we hope to understand if Efimosfermin alfa could be a new and effective treatment option for MASH.
Points clés
- This study is testing a new medicine for MASH liver disease.
- It aims to see if the medicine can improve liver scarring and damage.
- Some participants will receive the medicine, others a dummy treatment (placebo).
- It's a long-term study with regular health checks.
- Participation includes medical examinations, blood tests, and liver biopsies.
- Vous pouvez arrêter de participer à tout moment.
Qui peut être éligible ?
To be considered for this study, you need to be an adult, aged 18 or older. Both men and women are welcome to take part.
You must have been diagnosed with MASH, and doctors will need to confirm this with a liver biopsy. This biopsy will also show that your liver scarring is at a moderate (F2) or more advanced (F3) stage. The study will have specific criteria about what other health conditions might prevent you from joining, which your doctor will discuss with you.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Have you been diagnosed with MASH?
- Has a doctor confirmed your MASH with a liver biopsy?
- Has your biopsy shown moderate (F2) or more advanced (F3) liver scarring?
En quoi consiste la participation ?
If you join this study, you will be randomly assigned to one of three groups. One group will receive the new medicine, Efimosfermin alfa, and the other two groups will receive a placebo (a dummy treatment). Neither you nor your study doctor will know which treatment you are receiving until the end of the study. This is called 'double-blind' and helps ensure the results are fair.
You will have regular visits to the clinic over a number of years, initially for about a year (52 weeks) and then for extended follow-up (up to 4 years total). These visits will involve blood tests, physical examinations, and possibly imaging scans to check your liver health. A liver biopsy will also be taken at the start and potentially at other points to monitor changes in your liver scarring. You will also be asked about any side effects you might experience. All participants will be closely monitored throughout the study.
Risques et avantages potentiels
Emplacements (2)
- —Non vérifiéBelgique
- —Non vérifiéGrèce
Questions fréquentes
What is MASH?
MASH stands for Metabolic Dysfunction-Associated Steatohepatitis. It's a type of liver disease where fat builds up in the liver, causing inflammation and damage, which can lead to scarring.
What is 'fibrosis'?
Fibrosis means scarring in the liver. When the liver is damaged, it can form scar tissue. Too much scarring can stop the liver from working properly.
Qu'est-ce qu'un 'placebo' ?
A placebo is a dummy treatment. It looks exactly like the real medicine but doesn't contain any active ingredients. It helps us see if the new medicine is truly effective.
Combien de temps durera l'étude ?
The initial part of the study will last about 52 weeks (one year), but participants will be followed for a longer period, up to 48 months (four years).
Will I know if I'm getting the real medicine?
No, this is a 'double-blind' study, meaning neither you nor your study doctor will know whether you are receiving the active medicine or the placebo until the study ends.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.